Market
Will Novo Nordisk integrate Catalent's sites by end of 2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Official press releases from Novo Nordisk or Catalent, or credible news reports
Story
Novo Nordisk to Finalize $16.5 Billion Catalent Acquisition of Three Manufacturing Sites After FTC Approval
Dec 14, 2024, 03:45 PM
Novo Nordisk is poised to finalize its acquisition of three manufacturing sites from Catalent, following the Federal Trade Commission's (FTC) decision not to challenge the $16.5 billion acquisition by Novo Holdings of Catalent. This acquisition is expected to bolster Novo Nordisk's production capabilities, particularly in response to the growing demand for its anti-obesity drugs, including Wegovy and Ozempic. The deal has cleared all regulatory closing conditions, allowing Novo Nordisk to proceed with its plans to enhance its manufacturing capacity. The acquisition is strategically significant as Catalent is a key subcontractor in the production of Wegovy, which has seen increased demand due to its popularity in treating obesity.
View original story
Similar markets
Decrease • 25%
No change • 25%
Slightly increase • 25%
Significantly increase • 25%
No significant change • 25%
Increase by 1-5% • 25%
Increase by more than 5% • 25%
Decrease • 25%
Top 5 • 25%
Below Top 20 • 25%
Top 10 • 25%
Top 20 • 25%
Growth 5-10% • 25%
No growth • 25%
Growth above 10% • 25%
Growth below 5% • 25%